SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes

To assess the association between sodium-glucose cotransporter-2 (SGLT2) inhibitors and other second-line diabetes therapies with risk of cardiovascular disease (CVD), as well as conduct head-to-head comparisons between SGLT2 inhibitors.

Source: Mayo Clinic Proceedings - July 1, 2023 Category: Internal Medicine Authors: Wendy Wang, Lin Yee Chen, Rob F. Walker, Lisa S. Chow, Faye L. Norby, Alvaro Alonso, James S. Pankow, Pamela L. Lutsey Tags: Original article Source Type: research